ARTICLE | Company News
Amgen gets rights to Captisol formulation technology for BiTE AMG 330
July 28, 2017 7:52 PM UTC
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Amgen Inc. (NASDAQ:AMGN) exclusive, worldwide commercialization rights to combine Captisol formulation technology with AMG 330 to treat multiple indications.
Ligand received an undisclosed upfront payment and is eligible for milestones and royalties...